Annual Operating Profit
-$33.02 M
+$26.25 M+44.29%
31 March 2024
Summary:
VistaGen Therapeutics annual operaing income is currently -$33.02 million, with the most recent change of +$26.25 million (+44.29%) on 31 March 2024. During the last 3 years, it has fallen by -$15.09 million (-84.12%). VTGN annual operating profit is now -370922.47% below its all-time high of -$8900.00, reached on 31 December 2010.VTGN Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
-$14.23 M
-$2.10 M-17.28%
30 September 2024
Summary:
VistaGen Therapeutics quarterly operating income is currently -$14.23 million, with the most recent change of -$2.10 million (-17.28%) on 30 September 2024. Over the past year, it has dropped by -$7.45 million (-109.84%). VTGN quarterly operating profit is now -14226900.00% below its all-time high of -$100.00, reached on 30 September 2008.VTGN Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
-$45.60 M
-$7.45 M-19.52%
30 September 2024
Summary:
VistaGen Therapeutics TTM operating income is currently -$45.60 million, with the most recent change of -$7.45 million (-19.52%) on 30 September 2024. Over the past year, it has dropped by -$9.82 million (-27.44%). VTGN TTM operating profit is now -2072695.45% below its all-time high of -$2200.00, reached on 31 March 2007.VTGN TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VTGN Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +44.3% | -109.8% | -27.4% |
| 3 y3 years | -84.1% | -11.2% | -43.3% |
| 5 y5 years | -34.6% | -165.9% | -86.4% |
VTGN Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -84.1% | +44.3% | -109.8% | +28.1% | -43.3% | +29.3% |
| 5 y | 5 years | -84.1% | +44.3% | -355.7% | +28.1% | -207.8% | +29.3% |
| alltime | all time | <-9999.0% | +44.3% | <-9999.0% | +28.1% | <-9999.0% | +29.3% |
VistaGen Therapeutics Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$14.23 M(+17.3%) | -$45.60 M(+19.5%) |
| June 2024 | - | -$12.13 M(+6.8%) | -$38.15 M(+15.5%) |
| Mar 2024 | -$33.02 M(-44.3%) | -$11.36 M(+44.1%) | -$33.02 M(-2.6%) |
| Dec 2023 | - | -$7.88 M(+16.3%) | -$33.90 M(-5.3%) |
| Sept 2023 | - | -$6.78 M(-3.1%) | -$35.78 M(-23.0%) |
| June 2023 | - | -$7.00 M(-42.8%) | -$46.49 M(-21.6%) |
| Mar 2023 | -$59.27 M(+24.7%) | -$12.24 M(+25.3%) | -$59.27 M(-7.0%) |
| Dec 2022 | - | -$9.77 M(-44.2%) | -$63.72 M(-1.2%) |
| Sept 2022 | - | -$17.49 M(-11.6%) | -$64.50 M(+7.8%) |
| June 2022 | - | -$19.77 M(+18.5%) | -$59.81 M(+25.8%) |
| Mar 2022 | -$47.55 M(+165.1%) | -$16.69 M(+58.4%) | -$47.55 M(+28.3%) |
| Dec 2021 | - | -$10.54 M(-17.7%) | -$37.07 M(+16.5%) |
| Sept 2021 | - | -$12.80 M(+70.3%) | -$31.83 M(+42.6%) |
| June 2021 | - | -$7.51 M(+20.8%) | -$22.33 M(+24.5%) |
| Mar 2021 | -$17.93 M(-10.2%) | -$6.22 M(+17.4%) | -$17.94 M(+19.7%) |
| Dec 2020 | - | -$5.30 M(+60.9%) | -$14.98 M(+1.1%) |
| Sept 2020 | - | -$3.29 M(+5.5%) | -$14.82 M(-12.2%) |
| June 2020 | - | -$3.12 M(-4.3%) | -$16.87 M(-15.5%) |
| Mar 2020 | -$19.97 M(-18.6%) | -$3.26 M(-36.5%) | -$19.97 M(-11.0%) |
| Dec 2019 | - | -$5.14 M(-4.0%) | -$22.43 M(-8.3%) |
| Sept 2019 | - | -$5.35 M(-14.0%) | -$24.46 M(-7.8%) |
| June 2019 | - | -$6.22 M(+8.8%) | -$26.54 M(+8.2%) |
| Mar 2019 | -$24.53 M(+76.4%) | -$5.72 M(-20.2%) | -$24.53 M(+1.3%) |
| Dec 2018 | - | -$7.17 M(-3.6%) | -$24.21 M(+23.3%) |
| Sept 2018 | - | -$7.43 M(+76.5%) | -$19.63 M(+16.1%) |
| June 2018 | - | -$4.21 M(-22.1%) | -$16.91 M(+13.0%) |
| Mar 2018 | -$13.91 M(+41.6%) | -$5.40 M(+108.5%) | -$14.97 M(+23.6%) |
| Dec 2017 | - | -$2.59 M(-45.1%) | -$12.11 M(+2.7%) |
| Sept 2017 | - | -$4.71 M(+108.5%) | -$11.79 M(+16.0%) |
| June 2017 | - | -$2.26 M(-11.3%) | -$10.16 M(+3.4%) |
| Mar 2017 | -$9.82 M(-16.5%) | -$2.55 M(+12.4%) | -$9.82 M(-39.4%) |
| Dec 2016 | - | -$2.27 M(-26.5%) | -$16.20 M(+0.8%) |
| Sept 2016 | - | -$3.08 M(+60.3%) | -$16.08 M(-12.5%) |
| June 2016 | - | -$1.92 M(-78.4%) | -$18.38 M(+1.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | -$11.77 M(+73.6%) | -$8.93 M(+316.8%) | -$18.15 M(+45.2%) |
| Dec 2015 | - | -$2.14 M(-60.2%) | -$12.50 M(+8.9%) |
| Sept 2015 | - | -$5.39 M(+217.1%) | -$11.48 M(+59.3%) |
| June 2015 | - | -$1.70 M(-48.2%) | -$7.21 M(+6.3%) |
| Mar 2015 | -$6.78 M(+40.5%) | -$3.28 M(+193.5%) | -$6.78 M(+49.5%) |
| Dec 2014 | - | -$1.12 M(+0.3%) | -$4.53 M(-2.7%) |
| Sept 2014 | - | -$1.11 M(-12.4%) | -$4.66 M(-2.1%) |
| June 2014 | - | -$1.27 M(+22.9%) | -$4.76 M(-1.3%) |
| Mar 2014 | -$4.82 M(-29.0%) | -$1.03 M(-16.7%) | -$4.82 M(-15.4%) |
| Dec 2013 | - | -$1.24 M(+2.2%) | -$5.70 M(-10.6%) |
| Sept 2013 | - | -$1.21 M(-9.0%) | -$6.38 M(-6.8%) |
| June 2013 | - | -$1.33 M(-30.2%) | -$6.84 M(+0.7%) |
| Mar 2013 | -$6.79 M(-19.2%) | -$1.91 M(-0.4%) | -$6.79 M(-11.4%) |
| Dec 2012 | - | -$1.92 M(+14.3%) | -$7.67 M(-3.7%) |
| Sept 2012 | - | -$1.68 M(+30.6%) | -$7.96 M(-1.6%) |
| June 2012 | - | -$1.28 M(-53.9%) | -$8.09 M(-3.7%) |
| Mar 2012 | -$8.40 M(>+9900.0%) | -$2.79 M(+26.1%) | -$8.40 M(+49.5%) |
| Dec 2011 | - | -$2.21 M(+22.4%) | -$5.62 M(+64.7%) |
| Sept 2011 | - | -$1.81 M(+12.9%) | -$3.41 M(+112.1%) |
| June 2011 | - | -$1.60 M(>+9900.0%) | -$1.61 M(>+9900.0%) |
| Mar 2011 | - | -$5300.00(+178.9%) | -$11.40 K(+28.1%) |
| Dec 2010 | -$8900.00(-59.5%) | -$1900.00(-9.5%) | -$8900.00(+6.0%) |
| Sept 2010 | - | -$2100.00(0.0%) | -$8400.00(+10.5%) |
| June 2010 | - | -$2100.00(-25.0%) | -$7600.00(0.0%) |
| Mar 2010 | - | -$2800.00(+100.0%) | -$7600.00(-65.5%) |
| Dec 2009 | -$22.00 K(+34.1%) | -$1400.00(+7.7%) | -$22.00 K(-34.5%) |
| Sept 2009 | - | -$1300.00(-38.1%) | -$33.60 K(+3.7%) |
| June 2009 | - | -$2100.00(-87.8%) | -$32.40 K(+3.2%) |
| Mar 2009 | - | -$17.20 K(+32.3%) | -$31.40 K(+91.5%) |
| Dec 2008 | -$16.40 K | -$13.00 K(>+9900.0%) | -$16.40 K(+382.4%) |
| Sept 2008 | - | -$100.00(-90.9%) | -$3400.00(+3.0%) |
| June 2008 | - | -$1100.00(-50.0%) | -$3300.00(-26.7%) |
| Mar 2008 | - | -$2200.00(-4.3%) | -$4500.00(0.0%) |
| June 2007 | - | -$2300.00(+4.5%) | -$4500.00(+104.5%) |
| Mar 2007 | - | -$2200.00 | -$2200.00 |
FAQ
- What is VistaGen Therapeutics annual operaing income?
- What is the all time high annual operating profit for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual operating profit year-on-year change?
- What is VistaGen Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly operating profit year-on-year change?
- What is VistaGen Therapeutics TTM operating income?
- What is the all time high TTM operating profit for VistaGen Therapeutics?
- What is VistaGen Therapeutics TTM operating profit year-on-year change?
What is VistaGen Therapeutics annual operaing income?
The current annual operating profit of VTGN is -$33.02 M
What is the all time high annual operating profit for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual operaing income is -$8900.00
What is VistaGen Therapeutics annual operating profit year-on-year change?
Over the past year, VTGN annual operaing income has changed by +$26.25 M (+44.29%)
What is VistaGen Therapeutics quarterly operating income?
The current quarterly operating profit of VTGN is -$14.23 M
What is the all time high quarterly operating profit for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly operating income is -$100.00
What is VistaGen Therapeutics quarterly operating profit year-on-year change?
Over the past year, VTGN quarterly operating income has changed by -$7.45 M (-109.84%)
What is VistaGen Therapeutics TTM operating income?
The current TTM operating profit of VTGN is -$45.60 M
What is the all time high TTM operating profit for VistaGen Therapeutics?
VistaGen Therapeutics all-time high TTM operating income is -$2200.00
What is VistaGen Therapeutics TTM operating profit year-on-year change?
Over the past year, VTGN TTM operating income has changed by -$9.82 M (-27.44%)